Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Shukla Website

Suneet Shukla, Ph.D.

Selected Publications

1)  Shukla S, Chufan EE, Singh S, Skoumbourdis AP, Kapoor K, Boxer MB, Duveau DY, Thomas CJ, Talele TT, Ambudkar SV.
Elucidation of the structural basis of interaction of the BCR-ABL kinase inhibitor, nilotinib (Tasigna) with the human ABC drug transporter P-glycoprotein.
Leukemia. 28: 961-4, 2014.
2)  Prasad B, Evers R, Gupta A, Hop CE, Salphati L, Shukla S, Ambudkar SV, Unadkat JD.
Interindividual Variability in Hepatic Organic Anion-Transporting Polypeptides and P-Glycoprotein (ABCB1) Protein Expression: Quantification by Liquid Chromatography Tandem Mass Spectroscopy and Influence of Genotype, Age, and Sex.
Drug Metab. Dispos. 42: 78-88, 2014.
3)  Zhang H, Kathawala RJ, Wang YJ, Zhang YK, Patel A, Shukla S, Robey RW, Talele TT, Ashby CR, Ambudkar SV, Bates SE, Fu LW, Chen ZS.
Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance.
Int. J. Biochem. Cell Biol. 51: 111-9, 2014.
4)  Shukla S, Kouanda A, Silverton L, Talele TT, Ambudkar SV.
Pharmacophore modeling of nilotinib as an inhibitor of ABC drug transporters and BCR-ABL kinase using a 3D-QSAR approach.
Mol. Pharm. 2014.
5)  Bakhsheshian J, Wei BR, Chang KE, Shukla S, Ambudkar SV, Simpson RM, Gottesman MM, Hall MD.
Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2.
Proc. Natl. Acad. Sci. U.S.A. 110: 20801-6, 2013.
6)  Ansbro MR, Shukla S, Ambudkar SV, Yuspa SH, Li L.
Screening compounds with a novel high-throughput ABCB1-mediated efflux assay identifies drugs with known therapeutic targets at risk for multidrug resistance interference.
PLoS ONE. 8: e60334, 2013.
7)  Duveau DY, Hu X, Walsh MJ, Shukla S, Skoumbourdis AP, Boxer MB, Ambudkar SV, Shen M, Thomas CJ.
Synthesis and biological evaluation of analogues of the kinase inhibitor nilotinib as Abl and Kit inhibitors.
Bioorg. Med. Chem. Lett. 23: 682-6, 2013.
8)  Bhullar J, Natarajan K, Shukla S, Mathias TJ, Sadowska M, Ambudkar SV, Baer MR.
The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions.
PLoS ONE. 8: e71266, 2013.
9)  Natarajan K, Bhullar J, Shukla S, Burcu M, Chen ZS, Ambudkar SV, Baer MR.
The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms.
Biochem. Pharmacol. 85: 514-24, 2013.
10)  Sen R, Natarajan K, Bhullar J, Shukla S, Fang HB, Cai L, Chen ZS, Ambudkar SV, Baer MR.
The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.
Mol. Cancer Ther. 11: 2033-44, 2012.
11)  Shukla S, Schwartz C, Kapoor K, Kouanda A, Ambudkar SV.
Use of Baculovirus BacMam Vectors for Expression of ABC Drug Transporters in Mammalian Cells.
Drug Metab. Dispos. 40: 304-12, 2012.
12)  Kannan P, Telu S, Shukla S, Ambudkar SV, Pike VW, Halldin C, Gottesman MM, Innis RB, Hall MD.
The "Specific" P-Glycoprotein Inhibitor Tariquidar Is Also a Substrate and an Inhibitor for Breast Cancer Resistance Protein (BCRP/ABCG2).
ACS Chem Neurosci. 2: 82-9, 2011.
13)  Shukla S, Chen ZS, Ambudkar SV.
Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance.
Drug Resist. Updat. 15: 70-80, 2011.
14)  Shukla S, Ohnuma S, Ambudkar SV.
Improving cancer chemotherapy with modulators of ABC drug transporters.
Curr Drug Targets. 12: 621-30, 2011.
15)  Shukla S, Skoumbourdis AP, Walsh MJ, Hartz AM, Fung KL, Wu CP, Gottesman MM, Bauer B, Thomas CJ, Ambudkar SV.
Synthesis and characterization of a BODIPY conjugate of the BCR-ABL kinase inhibitor Tasigna (nilotinib): evidence for transport of Tasigna and its fluorescent derivative by ABC drug transporters.
Mol. Pharm. 8: 1292-302, 2011.
16)  Wang DS, Patel A, Shukla S, Zhang YK, Wang YJ, Kathawala RJ, Robey RW, Zhang L, Yang DH, Talele TT, Bates SE, Ambudkar SV, Xu RH, Chen ZS.
Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2.
Oncotarget. 2014.
17)  Wang YJ, Kathawala RJ, Zhang YK, Patel A, Kumar P, Shukla S, Fung KL, Ambudkar SV, Talele TT, Chen ZS.
Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1.
Biochem. Pharmacol. 2014.
18)  Shi Z, Tiwari AK, Shukla S, Robey RW, Singh S, Kim IW, Bates SE, Peng X, Abraham I, Ambudkar SV, Talele TT, Fu LW, Chen ZS.
Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
Cancer Res. 71: 3029-41, 2011.
19)  Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, Brendel C, Ambudkar SV, Neubauer A, Bates SE.
Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.
Drug Metab. Dispos. 38: 1371-80, 2010.
20)  Kumar A, Shukla S, Mandal A, Shukla S, Ambudkar SV, Prasad R.
Divergent signature motifs of nucleotide binding domains of ABC multidrug transporter, CaCdr1p of pathogenic Candida albicans, are functionally asymmetric and noninterchangeable.
Biochim. Biophys. Acta. 1798: 1757-66, 2010.
21)  Li L, Shukla S, Lee A, Garfield SH, Maloney DJ, Ambudkar SV, Yuspa SH.
The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature.
Cancer Res. 70: 4509-19, 2010.
22)  Robey RW, Obrzut T, Shukla S, Polgar O, Macalou S, Bahr JC, Di Pietro A, Ambudkar SV, Bates SE.
Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells.
Cancer Chemother. Pharmacol. 64: 575-83, 2009.
23)  Henrich CJ, Robey RW, Takada K, Bokesch HR, Bates SE, Shukla S, Ambudkar SV, McMahon JB, Gustafson KR.
Botryllamides: natural product inhibitors of ABCG2.
ACS Chem. Biol. 4: 637-47, 2009.
24)  Shukla S, Zaher H, Hartz A, Bauer B, Ware JA, Ambudkar SV.
Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice.
Pharm. Res. 26: 480-7, 2009.
25)  Sharma M, Manoharlal R, Shukla S, Puri N, Prasad T, Ambudkar SV, Prasad R.
Curcumin modulates efflux mediated by yeast ABC multidrug transporters and is synergistic with antifungals.
Antimicrob. Agents Chemother. 53: 3256-65, 2009.
26)  Deeken JF, Robey RW, Shukla S, Steadman K, Chakraborty AR, Poonkuzhali B, Schuetz EG, Holbeck S, Ambudkar SV, Bates SE.
Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen.
Mol. Pharmacol. 76: 946-56, 2009.
27)  Shi Z, Tiwari AK, Shukla S, Robey RW, Kim IW, Parmar S, Bates SE, Si QS, Goldblatt CS, Abraham I, Fu LW, Ambudkar SV, Chen ZS.
Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478.
Biochem. Pharmacol. 77: 781-93, 2009.
28)  Shukla S, Robey RW, Bates SE, Ambudkar SV.
Sunitinib (Sutent(R), SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ABC transporters, P-glycoprotein (ABCB1) and ABCG2.
Drug Metab. Dispos. 37(2): 359-65, 2009.
29)  Puri N, Gaur M, Sharma M, Shukla S, Ambudkar SV, Prasad R.
The amino acid residues of transmembrane helix 5 of multidrug resistance protein CaCdr1p of Candida albicans are involved in substrate specificity and drug transport.
Biochim. Biophys. Acta. 1788: 1752-61, 2009.
30)  Gardner ER, Ahlers CM, Shukla S, Sissung TM, Ockers SB, Price DK, Hamada A, Robey RW, Steinberg SM, Ambudkar SV, Dahut WL, Figg WD.
Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival.
BJU Int. 102: 1694-9, 2008.
31)  Shukla S, Wu CP, Ambudkar SV.
Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges.
Expert opinion on drug metabolism & toxicology. 4: 205-23, 2008.
32)  Shukla S, Sauna ZE, Ambudkar SV.
Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2.
Leukemia. 22: 445-7, 2008.
33)  Robey RW, Shukla S, Finley EM, Oldham RK, Barnett D, Ambudkar SV, Fojo T, Bates SE.
Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).
Biochem. Pharmacol. 75: 1302-12, 2008.
34)  Calcagno AM, Kim IW, Wu CP, Shukla S, Ambudkar SV.
ABC drug transporters as molecular targets for the prevention of multidrug resistance and drug-drug interactions.
Current drug delivery. 4: 324-33, 2007.
35)  Pawarode A, Shukla S, Minderman H, Fricke SM, Pinder EM, O'Loughlin KL, Ambudkar SV, Baer MR.
Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins.
Cancer Chemother. Pharmacol. 60: 179-88, 2007.
36)  Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW, Bates SE, Shen T, Ashby CR, Fu LW, Ambudkar SV, Chen ZS.
Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Cancer Res. 67: 11012-20, 2007.
37)  Wu CP, Shukla S, Calcagno AM, Hall MD, Gottesman MM, Ambudkar SV.
Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter.
Mol. Cancer Ther. 6: 3287-96, 2007.
38)  Paterson JK, Shukla S, Black CM, Tachiwada T, Garfield S, Wincovitch S, Ernst DN, Agadir A, Li X, Ambudkar SV, Szakacs G, Akiyama S, Gottesman MM.
Human ABCB6 localizes to both the outer mitochondrial membrane and the plasma membrane.
Biochemistry. 46: 9443-52, 2007.
39)  Brendel C, Scharenberg C, Dohse M, Robey RW, Bates SE, Shukla S, Ambudkar SV, Wang Y, Wennemuth G, Burchert A, Boudriot U, Neubauer A.
Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.
Leukemia. 21: 1267-75, 2007.
40)  Robey RW, Shukla S, Steadman K, Obrzut T, Finley EM, Ambudkar SV, Bates SE.
Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure.
Mol. Cancer Ther. 6: 1877-85, 2007.
41)  Limtrakul P, Chearwae W, Shukla S, Phisalphong C, Ambudkar SV.
Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Mol. Cell. Biochem. 296: 85-95, 2007.
42)  Henrich CJ, Robey RW, Bokesch HR, Bates SE, Shukla S, Ambudkar SV, Dean M, McMahon JB.
New inhibitors of ABCG2 identified by high-throughput screening.
Mol. Cancer Ther. 6: 3271-8, 2007.
43)  Shukla S, Wu CP, Nandigama K, Ambudkar SV.
The naphthoquinones, vitamin K3 and its structural analogue plumbagin, are substrates of the multidrug resistance linked ATP binding cassette drug transporter ABCG2.
Mol. Cancer Ther. 6: 3279-86, 2007.
44)  Rai V, Gaur M, Shukla S, Shukla S, Ambudkar SV, Komath SS, Prasad R.
Conserved Asp327 of walker B motif in the N-terminal nucleotide binding domain (NBD-1) of Cdr1p of Candida albicans has acquired a new role in ATP hydrolysis.
Biochemistry. 45: 14726-39, 2006.
45)  Chearwae W, Shukla S, Limtrakul P, Ambudkar SV.
Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin.
Mol. Cancer Ther. 5: 1995-2006, 2006.
46)  Shukla S, Robey RW, Bates SE, Ambudkar SV.
The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2.
Biochemistry. 45: 8940-51, 2006.
47)  Saini P, Prasad T, Gaur NA, Shukla S, Jha S, Komath SS, Khan LA, Haq QM, Prasad R.
Alanine scanning of transmembrane helix 11 of Cdr1p ABC antifungal efflux pump of Candida albicans: identification of amino acid residues critical for drug efflux.
J. Antimicrob. Chemother. 56: 77-86, 2005.
48)  Sauna ZE, Shukla S, Ambudkar SV.
Disulfiram, an old drug with new potential therapeutic uses for human cancers and fungal infections.
Mol Biosyst. 1: 127-34, 2005.
49)  Shukla S, Sauna ZE, Prasad R, Ambudkar SV.
Disulfiram is a potent modulator of multidrug transporter Cdr1p of Candida albicans.
Biochem. Biophys. Res. Commun. 322: 520-5, 2004.
50)  Shukla S, Ambudkar SV, Prasad R.
Substitution of threonine-1351 in the multidrug transporter Cdr1p of Candida albicans results in hypersusceptibility to antifungal agents and threonine-1351 is essential for synergic effects of calcineurin inhibitor FK520.
J. Antimicrob. Chemother. 54: 38-45, 2004.
51)  Shukla S, Saini P, Jha S, Ambudkar SV, Prasad R.
Functional characterization of Candida albicans ABC transporter Cdr1p.
Eukaryotic Cell. 2: 1361-75, 2003.
52)  Jha S, Karnani N, Dhar SK, Mukhopadhayay K, Shukla S, Saini P, Mukhopadhayay G, Prasad R.
Purification and characterization of the N-terminal nucleotide binding domain of an ABC drug transporter of Candida albicans: uncommon cysteine 193 of Walker A is critical for ATP hydrolysis.
Biochemistry. 42: 10822-32, 2003.
53)  Agrawal A, Shukla S, Kale RK.
Role of Ca2+ in radiation-induced damage in murine splenocytes.
Int. J. Radiat. Biol. 79: 733-46, 2003.
Click Here to View Collapsed Bibliography.

This page was last updated on 7/8/2014.